Greenhill Thoduguli Aff
| Tournament | Round | Opponent | Judge | Cites | Round Report | Open Source | Edit/Delete |
|---|---|---|---|---|---|---|---|
| Newman Smith | 1 | Lovejoy GL | Jimmy Wolf |
|
|
| |
| St Marks | 1 | Lexington AW | Aisha Bawany |
|
|
| |
| none | Finals | none | none |
|
|
| Tournament | Round | Report |
|---|---|---|
| Newman Smith | 1 | Opponent: Lovejoy GL | Judge: Jimmy Wolf 1AC - GHI v1 |
| St Marks | 1 | Opponent: Lexington AW | Judge: Aisha Bawany 1AC - Pricing v1 |
To modify or delete round reports, edit the associated round.
Cites
| Entry | Date |
|---|---|
0 - Contact InfoTournament: none | Round: Finals | Opponent: none | Judge: none Please let me know if you don’t have access to any articles/books I’ve got cards disclosed from and I’ll send you the full text! | 9/24/21 |
SEPOCT - GHI 1AC v1Tournament: Newman Smith | Round: 1 | Opponent: Lovejoy GL | Judge: Jimmy Wolf SO21 – 1AC – GHIFrameworkThe standard is maximizing expected well-being~1~ Policy focus - Ethical policymaking requires calculation of consequencesGvosdev 5 – Rhodes scholar, PhD from St. Antony’s College, executive editor of The National Interest (Nikolas, The Value(s) of Realism, SAIS Review 25.1, pmuse, AG) AND —and the one that had also been roundly condemned on moral grounds. ~2~ No moral intent/foresight distinction for states—it’s just avoiding responsibility.David Enoch 7 ~The Faculty of Law, The Hebrew University, Mount Scopus Campus, Jerusalem~, "INTENDING, FORESEEING, AND THE STATE," Legal Theory, 13 (2007), 69–99, pg. 90-1, beckert AND against the intending-foreseeing distinction when applied to state action than elsewhere. ~3~ Ethical agnosticism means we should default towards preventing extinction as a meta-constraint on all ethical theories.Nick Bostrom 13 ~Faculty of Philosophy and Oxford Martin School, Oxford~, "Existential Risk Prevention as Global Priority", Global Policy, Vol 4, Issue 1 (2013): 15-31, BE AND , finally, makes humanity more likely to want to realize human values. PlanPlan Text: The member nations of the World Trade Organization ought to reduce intellectual property protections for medicines.Contention 1 – Global Health Inequality (GHI)Subpoint A – Access to MedicineIP protections allow developed countries to maintain extended monopolies in pharma, disproportionately hurting low-income countriesBaker et al 17 (Dean Baker is an American macroeconomist and co-founder, with Mark Weisbrot, of the Center for Economic and Policy Research in Washington, D.C. He is credited as one of the first economists to have identified the 2007–08 United States housing bubble., Arjun Jayadev is an Associate Professor of Economics at Azim Premji University and University of Massachusetts Boston., Joseph Stiglitz is an American economist, public policy analyst, and a professor at Columbia University. He is a recipient of the Nobel Memorial Prize in Economic Sciences and the John Bates Clark Medal.), "Innovation, Intellectual Property, and Development: A BETTER SET OF APPROACHES FOR THE 21st CENTURY", July 2017, Azim Premji University and Columbia University, pg. 27-28, https://www8.gsb.columbia.edu/faculty/jstiglitz/sites/jstiglitz/files/IP20for2021st20Century20-20EN.pdf NT AND smaller that they are unlikely to affect significantly the overall pace of innovation. Patents and market exclusivity are vital to big pharma monopolies, preventing generics from entering the market and allowing heavily marked-up pricesKesselheim et al 16 (Aaron S. Kesselheim, MD, JD, MPH, Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School. Jerry Avorn, Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Ameet Sarpatwari is an Assistant Professor of Medicine at Harvard Medical School and the Assistant Director of the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital.), "The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform", Journal of the American Medical Association, 8-23-16, https://jamanetwork.com/journals/jama/article-abstract/2545691 NT AND settlement and agreed to wait until patent expiration to market its product.56 Big pharma monopolies are detrimental to developing countries – patent law and TRIPS both decrease access to medicineAhmediani and Nikfar 16 (Saeed Ahmadiani and Shekoufeh Nikfar both work in the Department of Pharmacoeconomics and Pharmaceutical Administration at Tehran University of Medical Sciences), "Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective", 5-4-16, DARU Journal of Pharmaceutical Sciences, pg. 2-3, DOI 10.1186/s40199-016-0151-z, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855755/ NT AND be considered as a breach of human rights as will be explained further. Pharma patents are rewarding failure and benefit the least innovative parts of the industryFeldman 8/8/21 (Robin Feldman’s work focuses on the role of intellectual property law in technology and innovation; drug patents, pricing, and health care law; and artificial intelligence and data. She is the Arthur J. Goldberg Distinguished Professor of Law, the Albert Abramson ’54 Distinguished Professor of Law Chair, and Director of the UC Hastings Center for Innovation (C4i).), "Our patent system is broken. And it could be stifling innovation.", The Washington Post, https://www.washingtonpost.com/outlook/2021/08/08/our-patent-system-is-broken-it-could-be-stifling-innovation/ NT AND system from time immemorial, hampering our ability to innovate in crucial areas. Subpoint B – Climate ChangeRemoving patents for drugs removes the incentive for pharma companies to merge by removing the common threat of patent cliffs, which solves innovation and increases drug researchFeldman 4/6/21 (Robin Feldman’s work focuses on the role of intellectual property law in technology and innovation; drug patents, pricing, and health care law; and artificial intelligence and data. She is the Arthur J. Goldberg Distinguished Professor of Law, the Albert Abramson ’54 Distinguished Professor of Law Chair, and Director of the UC Hastings Center for Innovation (C4i).), "Drug companies keep merging. Why that’s bad for consumers and innovation.", The Washington Post, https://www.washingtonpost.com/outlook/2021/04/06/drug-companies-keep-merging-why-thats-bad-consumers-innovation/ NT AND companies also spent proportionally less on research than their non-merged competitors. The pharma industry exacerbates climate change, with big pharma causing significantly more carbon emissions than even the automotive industryBelkhir 4/19/21 (Dr. Lotfi Belkhir, tenure track Associate Professor, Walter G. Booth School of Engineering Practice, and Class of 1962 Mechanical Engineering Endowed Chair in Eco-Entrepreneurship. Dr. Belkhir is a visionary and results-driven academic and business practitioner. He is a researcher, teacher, inventor and entrepreneurial leader with 17 years of distinguished industrial experience in sustainable and innovation-powered business creation and economic growth. Dr. Belkhir is an expert and thought-leader in the field of Total Sustainable Management, Eco entrepreneurship, digital convergence and its socio-environmental impact. Possesses proven leadership skills in research and development, IP protection, business development, finance, strategic planning, and general management. He possesses strong and successful international experience and alliances, public speaking, and relationship building. Multicultural, and fluent in English, French and Arabic, Dr. Belkhir earned his Ph.D. in condensed matter physics from SUNY and MBA in Management of Technology, Walden University.), "How big pharma contributes to climate change", Global News, first published 6-1-19 and updated 4-19-21, https://globalnews.ca/news/5330863/climate-change-pharmaceutical-companies/ NT AND level, namely Amgen Inc., Johnson and Johnson and Roche Holding AG. Warming causes extinction, mass inequality and guarantees every other impact—only the plan can reduce emissionsSpratt and Dunplop 19, David Spratt ~Research Director for Breakthrough National Centre for Climate Restoration, Melbourne, and co-author of Climate Code Red: The case for emergency action~ and Ian Dunlop ~member of the Club of Rome. Formerly an international oil, gas and coal industry executive, chairman of the Australian Coal Association, chief executive of the Australian Institute of Company Directors, and chair of the Australian Greenhouse Office Experts Group on Emissions Trading 1998-2000~, "Existential climate-related security risk: A scenario approach," Breakthrough - National Centre for Climate Restoration, May 2019, pg. 8-10, beckert. Brackets in original text AND elements, including Arctic sea-ice, West Antarctica and coral reefs. The plan solves - WTO is crucial to global equity and reduce povertyNarlikar, PhD, 18 AND lose for all, but particularly the poorest in developed and rising powers. | 9/24/21 |
Open Source
| Filename | Date | Uploaded By | Delete |
|---|---|---|---|
9/24/21 | thodugulin23@greenhillorg |
|